Buchanan Ingersoll Disqualified From Ritalin Suit

Law360, New York (July 30, 2008, 12:00 AM EDT) -- After escaping sanctions in the patent battle over a generic version of Ritalin LA, Celgene Corp. has won a bid to have Buchanan Ingersoll & Rooney PC booted from representing opponent KV Pharmaceutical Co. in the long-standing infringement suit over the attention deficit disorder drug.

On Monday, U.S. Magistrate Judge Madeline Cox Arleo granted Celgene's bid to disqualify Buchanan from the Hatch-Waxman dispute, handing the pharmaceutical giant a victory against the firm.

“The evidence thus supports the conclusion that Buchanan did not explain the material risk...
To view the full article, register now.